成吉思汗

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

朝5晚9

一 | 本网讯记者杨佳琳报道　　6月19日，我市建昌县人民检察院和朝阳市的凌源市人民检察院共同签定《关于大凌河流域生态环境和自然资源保护协作意见》，标志大凌河保护公益诉讼协作机制正式建立。

二 | 　　按照《意见》要求，双方明确建立联席会议、专门联络员、跨区域协同办案、信息共享等具体措施，加强两地检察机关协作配合，尤其是大凌河源头水源协同保护，加强大凌河流域生态环境和自然资源保护协作，提升检察监督的工作质效，突破跨区域公益诉讼办案壁垒，为两地公益检察跨区域协同履职、携手保护公益环境提供制度保障。　　双方还就各自公益诉讼工作开展情况、创新亮点工作进行了深入探讨和交流，并表示将深入秉持共融互促、优势互补、资源共享、共同发展的司法理念，积极构建协调有序、协同高效、协作创新的公益检察保护联动机制，合力打造一批高质量公益诉讼检察产品，为推动维护“区域经济一体化”发展法律秩序、促进两地生态文明建设和经济社会发展贡献检察力量。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。